TY - JOUR T1 - Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00738-2017 VL - 49 IS - 5 SP - 1700738 AU - Lorenzo Guglielmetti Y1 - 2017/05/01 UR - http://erj.ersjournals.com/content/49/5/1700738.abstract N2 - 5 years after its first approval by a stringent regulatory authority, the role of bedaquiline in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is well established, and acknowledged by existing guidance. However, in many regards, the global introduction of bedaquiline can hardly be considered as a success.Scale-up of introduction of bedaquiline, as part of optimised treatment regimens, is supported by growing evidence http://ow.ly/JCEV30aPLmq ER -